124 related articles for article (PubMed ID: 10362840)
1. Structural features in heparin that interact with VEGF165 and modulate its biological activity.
Ono K; Hattori H; Takeshita S; Kurita A; Ishihara M
Glycobiology; 1999 Jul; 9(7):705-11. PubMed ID: 10362840
[TBL] [Abstract][Full Text] [Related]
2. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.
Gengrinovitch S; Greenberg SM; Cohen T; Gitay-Goren H; Rockwell P; Maione TE; Levi BZ; Neufeld G
J Biol Chem; 1995 Jun; 270(25):15059-65. PubMed ID: 7797488
[TBL] [Abstract][Full Text] [Related]
3. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.
Soker S; Goldstaub D; Svahn CM; Vlodavsky I; Levi BZ; Neufeld G
Biochem Biophys Res Commun; 1994 Sep; 203(2):1339-47. PubMed ID: 7522446
[TBL] [Abstract][Full Text] [Related]
4. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.
Gitay-Goren H; Cohen T; Tessler S; Soker S; Gengrinovitch S; Rockwell P; Klagsbrun M; Levi BZ; Neufeld G
J Biol Chem; 1996 Mar; 271(10):5519-23. PubMed ID: 8621410
[TBL] [Abstract][Full Text] [Related]
5. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain.
Mamluk R; Gechtman Z; Kutcher ME; Gasiunas N; Gallagher J; Klagsbrun M
J Biol Chem; 2002 Jul; 277(27):24818-25. PubMed ID: 11986311
[TBL] [Abstract][Full Text] [Related]
6. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF.
Keck RG; Berleau L; Harris R; Keyt BA
Arch Biochem Biophys; 1997 Aug; 344(1):103-13. PubMed ID: 9244387
[TBL] [Abstract][Full Text] [Related]
7. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins.
Ashikari-Hada S; Habuchi H; Kariya Y; Kimata K
J Biol Chem; 2005 Sep; 280(36):31508-15. PubMed ID: 16027124
[TBL] [Abstract][Full Text] [Related]
8. Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2.
Ishihara M
Glycobiology; 1994 Dec; 4(6):817-24. PubMed ID: 7537556
[TBL] [Abstract][Full Text] [Related]
9. Enhanced ability of heparin-carrying polystyrene (HCPS) to bind to heparin-binding growth factors and to inhibit growth factor-induced endothelial cell growth.
Ishihara M; Ono K; Ishikawa K; Hattori H; Saito Y; Yura H; Akaike T; Ozeki Y; Tanaka S; Mochizuki H; Kurita A
J Biochem; 2000 May; 127(5):797-803. PubMed ID: 10788788
[TBL] [Abstract][Full Text] [Related]
10. Effect of FGF-1 and FGF-2 on VEGF binding to human umbilical vein endothelial cells.
Chen JH; Wang XC; Kan M; Sato JD
Cell Biol Int; 2001; 25(3):257-60. PubMed ID: 11352499
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of the heparin-binding domain of vascular endothelial growth factor.
Fairbrother WJ; Champe MA; Christinger HW; Keyt BA; Starovasnik MA
Structure; 1998 May; 6(5):637-48. PubMed ID: 9634701
[TBL] [Abstract][Full Text] [Related]
12. Regulation of vascular endothelial growth factor binding and activity by extracellular pH.
Goerges AL; Nugent MA
J Biol Chem; 2003 May; 278(21):19518-25. PubMed ID: 12637571
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper).
Komori Y; Nikai T; Taniguchi K; Masuda K; Sugihara H
Biochemistry; 1999 Sep; 38(36):11796-803. PubMed ID: 10512636
[TBL] [Abstract][Full Text] [Related]
14. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin.
Giraux JL; Matou S; Bros A; Tapon-Bretaudière J; Letourneur D; Fischer AM
Eur J Cell Biol; 1998 Dec; 77(4):352-9. PubMed ID: 9930660
[TBL] [Abstract][Full Text] [Related]
15. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects.
Bikfalvi A; Sauzeau C; Moukadiri H; Maclouf J; Busso N; Bryckaert M; Plouet J; Tobelem G
J Cell Physiol; 1991 Oct; 149(1):50-9. PubMed ID: 1719003
[TBL] [Abstract][Full Text] [Related]
16. Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor.
Ishihara M; Shaklee PN; Yang Z; Liang W; Wei Z; Stack RJ; Holme K
Glycobiology; 1994 Aug; 4(4):451-8. PubMed ID: 7827407
[TBL] [Abstract][Full Text] [Related]
17. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165.
Gengrinovitch S; Berman B; David G; Witte L; Neufeld G; Ron D
J Biol Chem; 1999 Apr; 274(16):10816-22. PubMed ID: 10196157
[TBL] [Abstract][Full Text] [Related]
18. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.
Park JE; Keller GA; Ferrara N
Mol Biol Cell; 1993 Dec; 4(12):1317-26. PubMed ID: 8167412
[TBL] [Abstract][Full Text] [Related]
19. Importance of 6-O-sulfate groups of glucosamine residues in heparin for activation of FGF-1 and FGF-2.
Ishihara M; Takano R; Kanda T; Hayashi K; Hara S; Kikuchi H; Yoshida K
J Biochem; 1995 Dec; 118(6):1255-60. PubMed ID: 8720143
[TBL] [Abstract][Full Text] [Related]
20. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.
Luque A; Carpizo DR; Iruela-Arispe ML
J Biol Chem; 2003 Jun; 278(26):23656-65. PubMed ID: 12716911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
